The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
|Podcasts|February 25, 2017
Podcast: This Week in Managed Care - Drug Cost Blame Game, and Other News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Advertisement
Every week, The American Journal of Managed Care® recaps the
This week included news that Republicans have an outline for replacing the Affordable Care Act, pharmacy benefit managers and pharmaceutical companies pointing fingers at one another over drug costs, and a report on engagement for patients with chronic conditions.
Listen below or through one of these podcast services:
iTunes:
TuneIn:
Stitcher:
Advertisement
Related to this article
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
FDA Approves First Symptomatic Dermographism Treatment
4
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
5